Mulberry Biotherapeutics, based in Wellesley, MA, was founded with the mission to develop novel targeted bacteria-mediated therapies for patients with neurofibromatosis type 2 (NF2) and other non-cancerous neoplasms. The company aims to deliver transformative improvements in health and quality of life for individuals affected by this rare genetic disorder. Their core product focuses on leveraging bacteria-mediated therapy to address the underlying causes and symptoms of NF2, a condition that affects approximately 1 in 25,000 individuals globally.

Notable figures associated with Mulberry Biotherapeutics include leading researchers and clinicians specializing in genetic disorders and innovative therapeutic approaches. The company has garnered attention from investors interested in rare disease treatment advancements. Key achievements include significant progress in preclinical studies demonstrating the potential efficacy of their targeted therapies. Overall, Mulberry Biotherapeutics is poised to make a substantial impact on the treatment landscape for NF2 and similar conditions, offering new hope to patients and families affected by these challenging disorders.